400mcg Sublingual Misoprostol as First Line Treatment

Introduction of 400mcg Sublingual Misoprostol as First Line Treatment in 11 Health Posts in Three Districts in Senegal

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01939457

Enrollment

641

Registered

2013-09-11

Start date

2011-09-30

Completion date

2012-08-31

Last updated

2013-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incomplete Abortion

Brief summary

Women presenting with incomplete abortion and eligible for treatment with misoprostol were offered 400mcg sublingual misoprostol for treatment. Based on existing literature, the study hypothesises that women can successfully be treated with misoprostol alone as first line treatment.

Interventions

DRUGMisoprostol

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* uterine size less than 12 weeks lmp * open cervical os * current or past vaginal bleeding * willing to provide contact information for follow-up * over 18 or with guardian consent

Exclusion criteria

* suspicion of ectopic pregnancy * intrauterine device in place * bad general health (infection, anemia, shoc)

Design outcomes

Primary

Measure	Time frame	Description
complete abortion	1 year	number of complete abortion with misoprostol treatment alone

Countries

Senegal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026